MEOBF (Mesoblast) ROCE %: 0.00% (As of Dec. 2025)


MEOBF Mesoblast Ltd MEOBF
47 GF Score
Price $1.55
! 4 Warning Signs
View Full Analysis

What is Mesoblast ROCE %?

Mesoblast MEOBF 47 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates MEOBF with a GF Score™ of 47/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mesoblast's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Mesoblast  (OTCPK:MEOBF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mesoblast ROCE % Related Terms

Mesoblast ROCE % Historical Data

* Premium members only.

The historical data trend for Mesoblast's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast ROCE % Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.74 -11.78 -10.12 -11.03 -12.53

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEOBF
47GF Score
Mesoblast Ltd MEOBF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast ROCE % Calculation

Mesoblast's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-80.059/( ( (669.153 - 73.243) + (784.683 - 102.626) )/ 2 )
=-80.059/( (595.91+682.057)/ 2 )
=-80.059/638.9835
=-12.53 %

Mesoblast's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=0/( ( (0 - 0) + (782.307 - 128.069) )/ 1 )
=0/( ( 0 + 654.238 )/ 1 )
=0/654.238
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Mesoblast (MEOBF) has a ROCE % of 0.00% as of Dec. 2025.
Is Mesoblast's ROCE % too high?
Mesoblast's current ROCE % is 0.00%. Overall, Mesoblast has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's ROCE % compare to VRTX and REGN?
Mesoblast's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Mesoblast's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (MEOBF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Mesoblast's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Mesoblast (MEOBF), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
47GF Score

Get the complete analysis for MEOBF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price